Efficacy and safety of 0.5% levofloxacin ophthalmic solution for the treatment of bacterial conjunctivitis in pediatric patients

2004 ◽  
Vol 137 (4) ◽  
pp. 789
Author(s):  
S.J. Lichtenstein ◽  
M. Rinehart
Keyword(s):  
Pediatric Patients ◽  
Ophthalmic Solution ◽  
Efficacy And Safety ◽  
Bacterial Conjunctivitis

scholarly journals Review of Azithromycin Ophthalmic 1% Solution (AzaSite®) for the Treatment of Ocular Infections

2012 ◽  
Vol 4 ◽  
pp. OED.S7791 ◽  
Author(s):  
Dominick L. Opitz ◽  
Jennifer S. Harthan
Keyword(s):  
Ophthalmic Solution ◽  
Clinical Indication ◽  
Efficacy And Safety ◽  
Broad Spectrum Antibiotic ◽  
Bacterial Conjunctivitis ◽  
Gram Negative ◽  
Ocular Infections ◽  
The Us ◽  
Vehicle Delivery ◽  
Atypical Bacteria

AzaSite® (azithromomycin 1.0%) ophthalmic solution was approved in 2007 by the US Food and Drug Administration (FDA) as the first commercially available formulation of ophthalmic azithromycin for the treatment of bacterial conjunctivitis. AzaSite® utilizes a vehicle delivery system called DuraSite®, which stabilizes and sustains the release of azithromycin to the ocular surface, leading to a longer drug residence time, less frequent dosing, and an increase in patient compliance. AzaSite® is a broad spectrum antibiotic, effective against Gram-positive, Gram-negative, and atypical bacteria. AzaSite® has been studied for the treatment of ocular conditions beyond its clinical indication. A number of clinical studies have evaluated its efficacy and safety in the management of ocular conditions such as bacterial conjunctivitis and blepharitis on both the pediatric and adult populations. This article aims to evaluate the peer-reviewed published literature on the use of azithromycin 1.0% ophthalmic for current and possible future ophthalmic uses.

Efficacy and Safety of 0.6% Pazufloxacin Ophthalmic Solution Versus Moxifloxacin 0.5% and Gatifloxacin 0.3% in Subjects with Bacterial Conjunctivitis: A Randomized Clinical Trial

2018 ◽  
Vol 34 (3) ◽  
pp. 250-255 ◽  
Author(s):  
Leopoldo Baiza-Durán ◽  
Oscar Olvera-Montaño ◽  
Arieh R. Mercado-Sesma ◽  
Aldo A. Oregon-Miranda ◽  
Alfredo Lizárraga-Corona ◽  
...  
Keyword(s):  
Clinical Trial ◽  
Randomized Clinical Trial ◽  
Ophthalmic Solution ◽  
Efficacy And Safety ◽  
Bacterial Conjunctivitis ◽  
Solution Versus

Efficacy and Safety of Besifloxacin Ophthalmic Suspension 0.6% Compared with Moxifloxacin Ophthalmic Solution 0.5% for Treating Bacterial Conjunctivitis

Ophthalmology ◽  
2009 ◽  
Vol 116 (9) ◽  
pp. 1615-1623.e1 ◽  
Author(s):  
Marguerite B. McDonald ◽  
Eugene E. Protzko ◽  
Lynne S. Brunner ◽  
Timothy W. Morris ◽  
Wolfgang Haas ◽  
...  
Keyword(s):  
Ophthalmic Solution ◽  
Efficacy And Safety ◽  
Bacterial Conjunctivitis ◽  
Ophthalmic Suspension

Efficacy and Safety of Besifloxacin Ophthalmic Suspension 0.6% in Pediatric Patients With Bacterial Conjunctivitis

2009 ◽  
Vol 80 (6) ◽  
pp. 296-297
Author(s):  
Timothy L. Comstock ◽  
Michael R. Paterno ◽  
Jennifer A. Lynch ◽  
Heleen H. DeCory ◽  
Dale W. Usner
Keyword(s):  
Pediatric Patients ◽  
Efficacy And Safety ◽  
Bacterial Conjunctivitis ◽  
Ophthalmic Suspension

Efficacy and Safety of Azithromycin 1.5% Eye Drops for Purulent Bacterial Conjunctivitis in Pediatric Patients

2010 ◽  
Vol 29 (3) ◽  
pp. 222-226 ◽  
Author(s):  
Dominique Bremond-Gignac ◽  
Patricia Mariani-Kurkdjian ◽  
Ariel Beresniak ◽  
Lamia El Fekih ◽  
Yasmin Bhagat ◽  
...  
Keyword(s):  
Pediatric Patients ◽  
Eye Drops ◽  
Efficacy And Safety ◽  
Bacterial Conjunctivitis
Sign in / Sign up

Export Citation Format

Share Document